Kinetic of Melatonin Subsequent to the Consumption of Melatonin-rich Food Supplements

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-13

Study Completion Date

2020-10-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is conducted to clinically document the melatonin bioavailability of two dietary supplements containing melatonin : one prolonged release tablet dosed at 1.9mg and one spray dosed at 1mg for 2 oral sprays.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Kinetic of Compounds of a Melatonin-based Formulation in Healthy Subjects

NCT05419466

Melatonin Bioavailability

COMPLETED NA

A Study to Investigate the Pharmacokinetics of Prolonged-release Melatonin Compared to Standard, Immediate-release Melatonin in Healthy Adults

NCT04067791

Healthy

COMPLETED PHASE1

Oral Bioavailability of Two Melatonin Supplements

NCT05835258

Bioavailability

COMPLETED NA

The Effectiveness of a Proprietary of a Botanical Extract on Sleep Quality

NCT06894108

Sleep

COMPLETED NA

Oral Nutritional Supplement Effect on HDL Function

NCT04529174

HDL

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Melatonin Bioavailability

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

spray before tablet

Group Type EXPERIMENTAL

a prolonged release tablet and a spray containing melatonin

Intervention Type DIETARY_SUPPLEMENT

prolonged release tablet is dosed at 1.9mg and spray is dosed at 1mg for 2 oral sprays.

tablet before spray

Group Type EXPERIMENTAL

a prolonged release tablet and a spray containing melatonin

Intervention Type DIETARY_SUPPLEMENT

prolonged release tablet is dosed at 1.9mg and spray is dosed at 1mg for 2 oral sprays.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

a prolonged release tablet and a spray containing melatonin

prolonged release tablet is dosed at 1.9mg and spray is dosed at 1mg for 2 oral sprays.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male between the ages of 18 and 45,
* In good general health, i.e., free of chronic conditions and not taking medication at the time of inclusion and/or long-term,
* Over 70 kg and with a body mass index between 18.5 and 24.9,
* Able and willing to participate in the research by complying with the procedures of the protocol, in particular concerning the taking of the product under study and the performance of sequential blood tests,
* Having freely signed the consent form after adequate information on the proposed study, in accordance with Good Clinical Practice and after submission of the information leaflet,
* Affiliated to a social security scheme or similar.

Exclusion Criteria

* Smoker,
* Drug addict,
* Subject with an alcohol consumption of more than 2 glasses per day,
* Taking a drug treatment or melatonin or a product containing melatonin within 48 hours prior to a kinetics visit,
* Known organic or functional abnormality of the urinary tree,
* Any medical condition that would involve a change in melatonin metabolism:

Drug intake: Fluvoxamine, 5- or 8-methoxypsoralen, cimetidine, carbamazepine and rifampicin, analgesics, Liver abnormality known or detected at the screening visit and judged to be clinically significant by the investigator, Known autoimmune disease,

* Subject assessed as "moderately" or "definitely" evening type,
* Known hypertension (\>140/90),
* Diagnosis of migraine by a health professional according to the International Headache Society (IHS) criteria revised in 2004,
* Wuth a sleep disorder,
* Thyroid dysfunction, hyperglycemia or anemia judged to be clinically significant by the investigator,
* Blood donation within one month prior to inclusion,
* A known organic or psychological abnormality (including a history of severe depression) that may bias the results of the study as judged by the investigator,
* Workers with atypical working hours (night work, staggered working hours),
* Known allergy or intolerance to any of the components of the product,
* Psychological or linguistic inability to understand and sign informed consent,
* Participant in another interventional clinical trial or during a period of exclusion from a previous clinical trial,
* Under legal protection (guardianship, curatorship) or deprived of his rights as a result of the administrative or judicial decision,
* Subject who has reached the maximum threshold for compensation for research provided for in the regulations.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes